Intellia – CRISPR Therapy Hits Phase 3 Endpoint

Summary Intellia Therapeutics reported that its in vivo CRISPR gene-editing therapy, lonvoguran ziclumeran (lonvo-z), met its Phase 3 primary endpoint in hereditary angioedema, reducing swelling attacks by 87% versus placebo and advancing toward FDA submission. What Happened Intellia announced positive Phase 3 data for lonvo-z,…